OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Clinical Immunology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus	109
Biologicals for moderate-to-severe plaque type psoriasis in pediatric patients	84
An updated review on Mendelian susceptibility to mycobacterial diseases– a silver jubilee celebration of its first genetic diagnosis	82
A review of disease burden and clinical management for generalized pustular psoriasis in China	78
Managing acute COVID-19 in immunocompromised pediatric patients	76
Genetic syndromes and autoimmunity: what do we know? Focus on Down and Turner syndrome	61
Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients	58
Pharmacogenetics of childhood uncontrolled asthma	58
A review of current biomarkers in chronic rhinosinusitis with or without nasal polyps	56
The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease	48
Ex vivo and in vivo T-cell depletion in allogeneic transplantation: towards less or non-cytotoxic conditioning regimens	44
Vitamin D as disease-modifying therapy for multiple sclerosis?	32
Clinical updates in neoadjuvant immunotherapy for melanoma before surgery	32
Predicting lupus low disease activity state and remission in SLE: novel insights	30
Epinephrine treatment of food-induced and other cause anaphylaxis in United States and Canadian Emergency Departments: a systematic review and meta-analysis	30
Lymphocyte-C-reactive protein ratio combined with albumin upon admission predicts coronary artery dilation and aneurysm formation in pediatric patients with Kawasaki disease: a retrospective cohort st	29
Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience	28
Responses of patients with juvenile idiopathic arthritis to methotrexate: a genomic outlook	26
Broadening the clinical spectrum of giant cell arteritis: from the classic cranial to the predominantly extracranial pattern of the disease	25
Precision medicine in the allergy clinic: the application of component resolved diagnosis	25
Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy	24
Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo	24
Anoikis and SPP1 in idiopathic pulmonary fibrosis: integrating bioinformatics, cell, and animal studies to explore prognostic biomarkers and PI3K/AKT signaling regulation	24
A critical review of dupilumab for adult patients with prurigo nodularis	24
How could our genetics impact COVID-19 vaccine response?	23

Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: lessons from treatment in adults and the way forward	22
An immunologist’s guide to immunosenescence and its treatment	21
Cellular mechanisms and clinical applications for phenocopies of inborn errors of immunity: infectious susceptibility due to cytokine autoantibodies	21
Targeting the microbiome in Crohn’s disease	20
Examining the autoimmune aspects of frontal fibrosing alopecia	20
Bradford Hill and breast implant illness: no evidence for causal association with breast implants	20
The Impact of Preeclampsia in Lupus Nephritis	20
What is the full potential of baricitinib in treating patients with COVID-19?	19
BRAF inhibitors and their immunological effects in malignant melanoma	19
Assessing the potential of epigenetic targets as biomarkers in the diagnosis and treatment of rheumatoid arthritis	18
The multidisciplinary approach to diagnosing inborn errors of immunity: a comprehensive review of discipline-based manifestations	18
A successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort	16
Telemedicine beyond the pandemic: challenges in the pediatric immunology clinic	16
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection	16
Tofacitinib for the treatment of active ankylosing spondylitis in adults	15
Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis	15
Immunobiology and treatment of cutaneous T-cell lymphoma	15
Will SARS-CoV-2 impact the incidence and nature of other respiratory infections?	15
Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis	15
Eosinophilic esophagitis: does age matter?	14
Bimekizumab for the treatment of psoriatic arthritis	14
Olfactory dysfunction in chronic rhinosinusitis: insights into the underlying mechanisms and treatments	13
Why do drug treatments fail in Sjögren’s disease? Considerations for treatment, trial design and interpretation of clinical efficacy	13
Molecular genotyping versus serological diagnosis for RH blood group typing in sickle cell patients	13
Aleukemic variant of T-cell large granular lymphocyte leukemia in patients with rheumatoid arthritis - diagnostically challenging subtype	13
Immune dysfunction in inborn errors of immunity causing malignancies	13
A critical evaluation of nemolizumab for prurigo nodularis	13
Peanut (Arachis hypogaea) allergen powder-dnfp for the mitigation of allergic reactions to peanuts in children and adolescents	12
Proportion of T follicular helper cells in peripheral blood of rheumatoid arthritis patients: a systematic review and meta-analysis	12
Biological drugs for the treatment of children with chronic spontaneous urticaria	12
Innovative treatments for severe uncontrolled chronic rhinosinusitis with nasal polyps	12
Machine learning method for the cellular phenotyping of nasal polyps from multicentre tissue scans	12
The methylenetetrahydrofolate reductase 1298 A>C polymorphism is associated with an increased risk of inflammatory bowel disease: evidence from a meta-analysis	12
Efficacy and safety of subcutaneous immunotherapy with polymerized allergen mixtures in polyallergic patients – ARES observational study	12
Pan-cancer analysis of the prognostic significance of ACKR2 expression and the related genetic/epigenetic dysregulations	11
The role of fibroblast in chronic rhinosinusitis with nasal polyps: a key player in the inflammatory process	11
Colorectal medullary carcinoma: a pathological subtype with intense immune response and potential to benefit from immune checkpoint inhibitors	11
A prospective single-arm study on the efficacy and safety of short-course oral corticosteroids followed by topical corticosteroids in patients with severe chronic rhinosinusitis with nasal polyps	11
New therapeutic concepts against ischemia-reperfusion injury in organ transplantation	11
The role of immune reconstitution in relapse after allogeneic hematopoietic stem cell transplantation	11
Prognostic factors for post-operative outcomes in chronic rhinosinusitis with nasal polyps: a systematic review	11
Pioglitazone as a potential modulator in autoimmune diseases: a review on its effects in systemic lupus erythematosus, psoriasis, inflammatory bowel disease, and multiple sclerosis	11
Update on virus-induced asthma exacerbations	10
The role of IL-6 and IL-6 blockade in COVID-19	10
Growth differentiation factor-15 as an emerging biomarker for identifying myositis	10
Machine learning approaches to improve disease management of patients with rheumatoid arthritis: review and future directions	10
Model-based computational precision medicine to develop combination therapies for autoimmune diseases	10
Generalized pustular psoriasis: current management status and unmet medical needs in Japan	10
Personalizing therapy selection in inflammatory bowel disease	10
IRF1 expression might be a biomarker of CD8+ T cell infiltration in cutaneous melanoma	10

Challenges and management of childhood noninfectious chronic uveitis	10
An update on VEXAS syndrome	10
Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine	10
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus	10
The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren’s syndrome related dry eye	9
More than a random association between chronic obstructive pulmonary disease and psoriatic arthritis: shared pathogenic features and implications for treatment	9
Re-evaluation of nailfold capillaroscopy in discriminating primary from secondary Raynaud’s phenomenon and in predicting systemic sclerosis: a randomised observational prospective cohort study	9
Comparison of high- and low-molecular-weight sensitizing agents causing occupational asthma: an evidence-based insight	9
How suitable is intravenous tocilizumab for the treatment of Graves’ ophthalmopathy?	9
Machine learning and artificial intelligence within pediatric autoimmune diseases: applications, challenges, future perspective	9
What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?	9
Could small molecules be used in combination with biologics for inflammatory bowel disease?	9
How best to manage relapse and remission in ANCA-associated vasculitis	9
Pathophysiology of rejection in kidney transplantation	9
Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients	9
Risk of infections in psoriasis: assessment and challenges in daily management	9
An evaluation of the recently approved drugs for treating atopic dermatitis in the context of their safety and efficacy: a systematic review and meta-analysis	9
An evaluation of anifrolumab for use in adults with systemic lupus erythematosus	9
Filgotinib in rheumatoid arthritis	9
Clinical guide to eosinophilic fasciitis: straddling dermatology and rheumatology	8
Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies	8
Pathogen-specific cell-mediated immunity to guide the management of cytomegalovirus in solid organ transplantation: state of the art clinical review	8
The (apparent) antibody paradox in COVID-19	8
Corticosteroid-eluting implants for the management of chronic rhinosinusitis with or without nasal polyps	8
Managing psoriatic arthritis in different clinical scenarios	8
Rationale for IL-37 as a novel therapeutic agent in inflammation	8
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications	8
Genetic variations in the human immune system influence susceptibility to tegumentary leishmaniasis: a systematic review and meta-analysis	8
Systemic therapy in juvenile localized scleroderma	8
Role of tight junction proteins in shaping the immune milieu of malignancies	8
Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician	8
Food immunotherapy: current status and future needs	8
Role of CD68 in the tumor immune microenvironment in Hodgkin’s lymphoma	8
Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives	8
Biomarkers guiding biological therapeutic strategies in chronic rhinosinusitis with nasal polyps: an emerging challenge	8
Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy	8
Circulating NT-proANP level is a predictor of mortality for systemic sclerosis: a retrospective study of an Italian cohort	8
Recent insights into the impacts of COVID-19 on pediatric asthma	8
Could we co-opt the cannabinoid system for asthma therapy?	8
Pediatric chronic spontaneous urticaria: a brief clinician’s guide	8
Mast cell activation: beyond histamine and tryptase	8
Novel insights into central compartment atopic disease - a literature review	8
Tapinarof cream for the topical treatment of plaque psoriasis in adults	8
What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?	8
Epstein–Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge	7
The clinical role of anakinra in the armamentarium against familial Mediterranean fever	7
Matrix metalloproteinases in chronic rhinosinusitis	7
Upadacitinib for the treatment of adult patients with active psoriatic arthritis	7
Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate	7
Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives	7
Tackling medical misinformation in allergy and immunology practice	7
Isolation and analysis of the exosomal membrane proteins in bullous pemphigoid	7
How to and should we target EBV in MS?	7
Oral immunotherapy for food allergy in children: is it worth it?	7
Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm	7
Correction	7
The relationship between bullous pemphigoid and renal disease and related treatments: a review of the current literature	7
Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial	7
Autoimmune hemolytic anemia: causes and consequences	7